Revenue: As of FY2026 Q1, the actual value is USD 0.EPS: As of FY2026 Q1, the actual value is USD -0.85.EBIT: As of FY2026 Q1, the actual value is USD -2.749 M.All figures are in thousands of U.S. dollars unless otherwise specified .<h4>Operational Metrics</h4><ul><li>Research and Development (R&amp;D) Expenses:<ul><li>For the three months ended March 31, 2026, R&amp;D expenses were $1,370, marking a 133.3% increase compared to $590 for the same period in 2025 . This rise was primarily due to higher subcontractor and consultant expenses related to toxicology studies, product development, and GMP manufacturing, alongside non-cash share-based compensation expenses .</li></ul></li><li>General and Administrative (G&amp;A) Expenses:<ul><li>G&amp;A expenses were $1,379 for the three months ended March 31, 2026, an increase of 27.3% from $1,060 in the prior year’s period . This increase was mainly driven by higher professional services costs and non-cash share-based compensation expenses .</li></ul></li><li>Total Operating Expenses:<ul><li>Total operating expenses for the three months ended March 31, 2026, reached $2,749, up from $1,650 for the same period in 2025 .</li></ul></li><li>Operating Loss:<ul><li>The operating loss for the three months ended March 31, 2026, was $2,749, compared to $1,650 for the same period in 2025 .</li></ul></li><li>Financial Expense (Income), Net:<ul><li>The company reported a financial income, net of -$16 for the three months ended March 31, 2026, a change from a financial expense of $85 for the same period in 2025 .</li></ul></li><li>Net Loss:<ul><li>The net loss for the three months ended March 31, 2026, was $2,733, an increase of 58.8% from $1,735 for the same period in 2025 . This was primarily due to higher R&amp;D and G&amp;A expenses .</li></ul></li><li>Loss Per Share, Basic and Diluted:<ul><li>Loss per share was $0.85 for the three months ended March 31, 2026, compared to $3.84 for the same period in 2025 .</li></ul></li><li>Weighted Average Number of Ordinary Shares Outstanding:<ul><li>The weighted average number of ordinary shares outstanding was 3,230,378 for the three months ended March 31, 2026, significantly higher than 451,990 for the same period in 2025 .</li></ul></li></ul><h4>Balance Sheet Highlights</h4><ul><li>Cash and Cash Equivalents:<ul><li>Cash and cash equivalents stood at $2,413 as of March 31, 2026, a decrease from $5,991 as of December 31, 2025 . This decline reflects ongoing operating expenses for preclinical and clinical readiness activities .</li></ul></li><li>Total Current Assets:<ul><li>Total current assets were $4,065 as of March 31, 2026, down from $6,637 as of December 31, 2025 .</li></ul></li><li>Total Assets:<ul><li>Total assets were $4,602 as of March 31, 2026, compared to $7,215 as of December 31, 2025 .</li></ul></li><li>Total Current Liabilities:<ul><li>Total current liabilities were $4,060 as of March 31, 2026, an increase from $2,758 as of December 31, 2025 .</li></ul></li><li>Total Liabilities:<ul><li>Total liabilities were $4,311 as of March 31, 2026, compared to $4,612 as of December 31, 2025 .</li></ul></li><li>Total Shareholders’ Equity (Capital Deficiency):<ul><li>Total shareholders’ equity was $291 as of March 31, 2026, a decrease from $2,603 as of December 31, 2025 .</li></ul></li><li>Subsequent Capital Raising:<ul><li>Subsequent to quarter-end, Silexion Therapeutics Corp. generated approximately $1,000 in gross proceeds through a May 2026 warrant exercise inducement transaction and utilization of its at-the-market facility . These actions have raised the company’s shareholders’ equity above the $2,500 minimum required for Nasdaq Capital Market continued listing .</li></ul></li></ul><h4>Outlook / Guidance</h4>Silexion Therapeutics Corp. expects to initiate its Phase 2⁄3 clinical trial of SIL204 in locally advanced pancreatic cancer in the second quarter of 2026, pending regulatory approvals in Israel and Germany . The study is planned for leading oncology centers across Germany, additional EU member states, and Israeli sites . The company continues to evaluate financing alternatives to support the advancement of SIL204 into clinical trials .

SILEXION THERAPEUTICS CORP C/WTS EXP 15/08/2029 (TO PUR COM) | 8-K: FY2026 Q1 Revenue: USD 0